Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $316,920.00 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $26.41, for a total transaction of $316,920.00. Following the completion of the transaction, the chief operating officer now directly owns 72,363 shares of the company’s stock, valued at $1,911,106.83. This trade represents a 14.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Eben Tessari also recently made the following trade(s):

• On Monday, April 14th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $20.48, for a total transaction of $245,760.00.

Kiniksa Pharmaceuticals Trading Down 2.2%

NASDAQ KNSA opened at $26.12 on Thursday. The company has a 50-day moving average price of $23.11 and a two-hundred day moving average price of $21.44. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $17.38 and a 52 week high of $28.56. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -186.56 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same period in the previous year, the firm posted ($0.25) earnings per share. The business’s revenue was up 72.5% on a year-over-year basis. As a group, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after purchasing an additional 568 shares during the period. US Bancorp DE acquired a new stake in Kiniksa Pharmaceuticals in the first quarter worth about $33,000. Asset Management One Co. Ltd. bought a new position in Kiniksa Pharmaceuticals in the 1st quarter valued at about $41,000. Wealthquest Corp acquired a new position in Kiniksa Pharmaceuticals during the 1st quarter valued at about $42,000. Finally, Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals during the 4th quarter valued at about $61,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Jefferies Financial Group lifted their target price on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, April 29th. Citigroup began coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $38.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.